Next Article in Journal
Exosomes in Cancer Diagnostics
Next Article in Special Issue
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy
Previous Article in Journal
Acknowledgement to Reviewers of Cancers in 2016
Previous Article in Special Issue
Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Cancers 2017, 9(1), 7; doi:10.3390/cancers9010007

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

1
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
2
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Emmanuel S. Antonarakis
Received: 29 November 2016 / Revised: 4 January 2017 / Accepted: 5 January 2017 / Published: 11 January 2017
(This article belongs to the Special Issue AR Signaling in Human Malignancies: Prostate Cancer and Beyond)
View Full-Text   |   Download PDF [263 KB, uploaded 11 January 2017]

Abstract

In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signaling biology has dramatically improved, and it has become apparent that the AR can modulate a number of other well-described oncogenic signaling pathways. Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling in promoting the growth and progression of several cancers other than prostate, and early phase clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in several of these malignancies. In this article, we provide an overview of the evidence supporting the use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale for targeting AR-signaling across tumor types. View Full-Text
Keywords: prostate cancer; breast cancer; bladder cancer; renal cell carcinoma; pancreatic cancer; ovarian cancer; hepatocellular cancer; ovarian cancer; endometrial cancer; androgen receptor prostate cancer; breast cancer; bladder cancer; renal cell carcinoma; pancreatic cancer; ovarian cancer; hepatocellular cancer; ovarian cancer; endometrial cancer; androgen receptor
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schweizer, M.T.; Yu, E.Y. AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers 2017, 9, 7.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top